Mekong Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 24-10-2024
- Paid Up Capital ₹ 0.10 M
as on 24-10-2024
- Company Age 6 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.89 Cr
as on 24-10-2024
- Revenue -11.03%
(FY 2023)
- Profit -5.13%
(FY 2023)
- Ebitda 16.92%
(FY 2023)
- Net Worth 22.60%
(FY 2023)
- Total Assets 47.57%
(FY 2023)
About Mekong Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.89 Cr.
Maheshwar Suryapet and Suryapet Sarika serve as directors at the Company.
- CIN/LLPIN
U74999TG2018PTC125052
- Company No.
125052
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Jun 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Mekong Pharmaceuticals Private Limited offer?
Mekong Pharmaceuticals Private Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, API Intermediate, Industrial Chemicals & Supplies, Aldehydes, Chemical Reagents & Catalysts, Inorganic Salts, Industrial Chemicals, Bromine Compound, Chemical Compound, Cosmetics, Hair & Beauty Products.
Who are the key members and board of directors at Mekong Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Maheshwar Suryapet  | Director | 12-Jun-2018 | Current |
| Suryapet Sarika | Director | 12-Jun-2018 | Current |
Financial Performance of Mekong Pharmaceuticals.
Mekong Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 11.03% decrease. The company also saw a slight decrease in profitability, with a 5.13% decrease in profit. The company's net worth Soared by an impressive increase of 22.6%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mekong Pharmaceuticals?
In 2023, Mekong Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Greenovel Life Sciences Private LimitedActive 4 years 4 monthsMaheshwar Suryapet is a mutual person
Charges (Loans)
₹18.90 M
₹0
Charges Breakdown by Lending Institutions
- Canara Bank : 1.79 Cr
- Axis Bank Limited : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 23 Sep 2021 | Axis Bank Limited | ₹1.00 M | Open |
| 17 Dec 2020 | Canara Bank | ₹1.79 Cr | Open |
How Many Employees Work at Mekong Pharmaceuticals?
Unlock and access historical data on people associated with Mekong Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mekong Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mekong Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.